Selinexor (combination therapy)

DRUG2 trials

Sponsors

Karyopharm Therapeutics Inc, Beijing Friendship Hospital

Conditions

CAEBVEBVLymphohistiocytosisRelapsed/Refractory Diffuse Large B-cell Lymphoma

Phase 2

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Active, not recruitingNCT04442022

Karyopharm Therapeutics IncRelapsed/Refractory Diffuse Large B-cell Lymphoma

Start: 2020-09-03End: 2026-12-01Target: 501Updated: 2026-07-02

Golidocitinib Combined With Selinexor for CAEBVD

RecruitingNCT07369739

Beijing Friendship HospitalCAEBV, EBV, Lymphohistiocytosis

Start: 2026-01-01End: 2028-01-01Target: 28Updated: 2026-01-27